CROCI, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 2.015
EU - Europa 1.276
AS - Asia 424
AF - Africa 123
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 3.847
Nazione #
US - Stati Uniti d'America 1.996
GB - Regno Unito 372
CN - Cina 171
DE - Germania 167
SE - Svezia 162
IT - Italia 152
VN - Vietnam 148
UA - Ucraina 91
CH - Svizzera 67
RU - Federazione Russa 56
IE - Irlanda 52
IN - India 51
FR - Francia 48
CI - Costa d'Avorio 40
TG - Togo 39
SG - Singapore 28
ZA - Sudafrica 28
EE - Estonia 26
BG - Bulgaria 25
CA - Canada 19
BE - Belgio 17
RO - Romania 14
FI - Finlandia 9
JP - Giappone 7
NG - Nigeria 7
NL - Olanda 7
SC - Seychelles 7
IR - Iran 5
JO - Giordania 5
CL - Cile 4
GR - Grecia 4
PL - Polonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BD - Bangladesh 2
EG - Egitto 2
HR - Croazia 2
ID - Indonesia 2
AE - Emirati Arabi Uniti 1
BR - Brasile 1
ES - Italia 1
HK - Hong Kong 1
IQ - Iraq 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 3.847
Città #
Southend 318
Chandler 317
Fairfield 268
Ashburn 178
Woodbridge 127
Wilmington 123
Seattle 122
Houston 120
Ann Arbor 106
Dong Ket 87
Cambridge 85
Princeton 75
Jacksonville 59
Bern 58
Dublin 52
Abidjan 40
Lomé 39
Westminster 32
Padova 29
Nanjing 28
Singapore 25
Sofia 25
Bremen 24
Bologna 22
Beijing 21
Berlin 20
Redwood City 18
Brussels 17
Shenyang 17
Jinan 16
Milan 15
Ottawa 15
Saint Petersburg 15
Turin 12
Hebei 11
Nanchang 11
Changsha 10
San Diego 10
Boardman 9
Mülheim 9
Guangzhou 8
Jiaxing 8
New York 8
Tianjin 8
Dearborn 7
Helsinki 7
Kuban 7
Mahé 7
Zhengzhou 7
Abeokuta 6
Des Moines 6
Moscow 6
Tokyo 6
Amman 5
Bulle 5
Bühl 5
Washington 5
Amsterdam 4
Leawood 4
London 4
Redmond 4
Taizhou 4
Verona 4
Zanjan 4
Chieti 3
Mountain View 3
Ningbo 3
Olalla 3
Phoenix 3
Taiyuan 3
Toronto 3
Catania 2
Falls Church 2
Frankfurt Am Main 2
Haikou 2
Hanoi 2
Henderson 2
Jakarta 2
Kunming 2
Lanzhou 2
Lappeenranta 2
Los Angeles 2
Medford 2
Montechiarugolo 2
Muizenberg 2
Pitesti 2
San Francisco 2
Stockholm 2
Ulan-ude 2
Wroclaw 2
Alexandria 1
Andover 1
Auckland 1
Baghdad 1
Bochum 1
Buffalo 1
Cagliari 1
Casoria 1
Central 1
Centro 1
Totale 2.793
Nome #
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 202
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 167
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 151
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 145
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 141
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 140
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 138
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 137
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 134
Antimetastatic activity of a preventive cancer vaccine. 128
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 126
Immunological prevention of a multigene cancer syndrome 126
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 125
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 122
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 121
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 117
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 116
In silico modeling and in vivo efficacy of cancer preventive vaccinations 113
Isolation and in vitro differentiation of human Mesenchymal Stem Cells from new alternative sources: fetal membranes and placenta 112
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 109
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 108
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 108
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 105
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 104
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 103
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 102
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 95
null 94
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 93
Translational immunomics of cancer prevention. 92
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 87
Toward the definition of immunosuppressive regimens with antitumor activity. 87
Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas. 60
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes 49
Totale 3.957
Categoria #
all - tutte 9.362
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.362


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.109 134 26 20 62 121 104 146 165 140 86 44 61
2020/2021559 116 44 21 30 11 30 8 28 61 30 25 155
2021/2022699 66 17 55 24 54 27 18 48 26 57 178 129
2022/2023981 117 146 61 146 54 71 21 46 128 38 68 85
2023/2024209 9 41 7 26 17 48 12 18 5 11 6 9
2024/202555 55 0 0 0 0 0 0 0 0 0 0 0
Totale 3.957